Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CSBR | CHAMPIONS ONCOLOGY, INC. | 2026-07-31 14:29:51 | 5.39 | -0.33 | -5.68 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSBR | 0000771856 | CHAMPIONS ONCOLOGY, INC. | US15870P3073 | 549300O8WKLP8QEG5U47 | 521401755 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 0430 | DE | 855 N. WOLFE STREET | BALTIMORE | MD | 21205 | UNITED STATES | US | 410-369-0365 | 855 N. WOLFE STREET, BALTIMORE, MD, 21205 | 855 N. WOLFE STREET, BALTIMORE, MD, 21205 | CHAMPIONS BIOTECHNOLOGY, INC. | — | 2007 | — | — | — | 28,600,000 | 14,007,159 | 13,893,569 | Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist. | 2026-07-30 19:43:57 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2026 | 28,600,000 | 13,200,000 | 85.7143 | 13,893,569 | 116,399 | 0.8449 |
| 2025 | 15,400,000 | -6,600,000 | -30 | 13,777,170 | 183,404 | 1.3492 |
| 2024 | 22,000,000 | -6,000,000 | -21.4286 | 13,593,766 | 134,227 | 0.9973 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Brady Davis | President | 2025 | 177,083 | 0 | 0 | — | 0 | 177,083 |
| David Miller | Chief Financial Officer | 2025 | 278,333 | 30,000 | 0 | — | 0 | 315,777 |
| Ronnie Morris | Chief Executive Officer | 2025 | 400,000 | 200,000 | 0 | — | 0 | 600,000 |
| David Miller | Chief Financial Officer | 2024 | 260,000 | 0 | 0 | — | 0 | 260,000 |
| Brady Davis | President | 2024 | 425,000 | 75,000 | 0 | — | 0 | 1,346,210 |
| Fiscal Year | Employee Count |
|---|---|
| 2026 | 214 |
| 2025 | 213 |
| 2024 | 210 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Revenue | 59,425,000 | 56,944,000 | 50,155,000 |
| Cost Of Revenue | 30,900,000 | 28,389,000 | 29,401,000 |
| Gross Profit | 28,525,000 | 28,555,000 | 20,754,000 |
| Research And Development Expenses | 9,084,000 | 6,825,000 | 9,544,000 |
| General And Administrative Expenses | 11,152,000 | 9,339,000 | 11,067,000 |
| Operating Expenses | 29,665,000 | 24,002,000 | 28,110,000 |
| Operating Income | -1,140,000 | 4,553,000 | -7,356,000 |
| Net Income | -1,175,000 | 4,701,000 | -7,276,000 |
| Earnings Per Share Basic | -0.08 | 0.34 | -0.54 |
| Earnings Per Share Diluted | -0.08 | 0.33 | -0.54 |
| Weighted Average Shares Outstanding Basic | 13,832,385 | 13,659,786 | 13,547,604 |
| Weighted Average Shares Outstanding Diluted | 13,832,385 | 14,266,781 | 13,547,604 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Cash And Cash Equivalents | 4,872,000 | 9,785,000 | 2,618,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 13,178,000 | 11,234,000 | 9,526,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,169,000 | 1,350,000 | 1,495,000 |
| Total Assets Current | 19,219,000 | 22,369,000 | 13,639,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,526,000 | 4,375,000 | 5,721,000 |
| Other Assets Non Current | 212,000 | 185,000 | 185,000 |
| Total Assets Non Current | 7,770,000 | 9,975,000 | 12,493,000 |
| Total Assets | 26,989,000 | 32,344,000 | 26,132,000 |
| Accounts Payable | 6,903,000 | 4,248,000 | 5,800,000 |
| Deferred Revenue | 8,828,000 | 15,443,000 | 12,094,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 79,000 | 135,000 | 150,000 |
| Total Liabilities Current | 19,922,000 | 23,853,000 | 21,541,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 7,000 | 85,000 | 401,000 |
| Total Liabilities Non Current | 2,999,000 | 4,719,000 | 6,494,000 |
| Total Liabilities | 22,921,000 | 28,572,000 | 28,035,000 |
| Common Stock | 14,000 | 14,000 | 14,000 |
| Retained Earnings | -81,067,000 | -79,892,000 | -84,593,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 3,939,000 | 3,772,000 | -1,903,000 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Depreciation And Amortization | 1,377,000 | 1,640,000 | 1,867,000 |
| Share Based Compensation Expense | 1,237,000 | 654,000 | 1,118,000 |
| Other Non Cash Income Expense | -111,000 | -293,000 | -435,000 |
| Change In Accounts Receivable | 2,002,000 | 1,436,000 | 1,991,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 16,000 | 0 | 169,000 |
| Change In Accounts Payable | 2,558,000 | -1,749,000 | 465,000 |
| Change In Other Liabilities | 37,000 | 395,000 | -109,000 |
| Cash From Operating Activities | -4,472,000 | 7,386,000 | -6,137,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 564,000 | 389,000 | 836,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -540,000 | -389,000 | -836,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | 0 | 634,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 99,000 | 170,000 | -527,000 |
| Change In Cash | -4,913,000 | 7,167,000 | -7,500,000 |
| Cash At End Of Period | 4,872,000 | 9,785,000 | 2,618,000 |
| Income Taxes Paid | 242,000 | — | — |
| Interest Paid | 600 | 3,000 | 6,000 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Earnings Per Share | -0.08 | 0.34 | -0.54 |
| Price To Earnings Ratio | -74.5 | 21.0294 | -8.9815 |
| Earnings Growth Rate | -123.5294 | -162.963 | 38.4615 |
| Price Earnings To Growth Ratio | 0.6031 | -0.129 | -0.2335 |
| Book Value Per Share | 0.2941 | 0.2761 | -0.1405 |
| Price To Book Ratio | 20.2657 | 25.8928 | -34.5275 |
| Ebitda | 444,000 | 6,341,000 | -5,409,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 528,000 | 294,000 | 402,000 |
| Free Cash Flow | -5,000,000 | 7,092,000 | -6,539,000 |
| Return On Equity | -0.2983 | 1.2463 | 3.8234 |
| One Year Beta | 0.4059 | 0.8282 | -0.2535 |
| Three Year Beta | 0.5052 | 0.4064 | 0.2183 |
| Five Year Beta | 0.3985 | 0.5026 | 0.7912 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| ACKERMAN JOEL | Director | 2025-11-05 | 21,216 | A | 21,216 |
| TOBIN SCOTT R | Director, 10% owner | 2025-11-05 | 25,460 | A | 25,460 |
| Mendelson Daniel Newman | Director | 2025-11-05 | 13,790 | A | 13,790 |
| SIDRANSKY DAVID | Director | 2025-11-05 | 21,216 | A | 21,216 |
| Breitfeld Philip P. | Director | 2025-11-05 | 13,790 | A | 13,790 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 2026-06-30 | 75,000 | 12,252 | 6.1214 |
| Mesirow Financial Investment Management, Inc. | 2026-06-30 | 97,328 | 15,800 | 6.16 |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 125,540 | 21,833 | 5.75 |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 443,864 | 77,177 | 5.7512 |
| MORGAN STANLEY | 2026-03-31 | 1,393,225 | 242,300 | 5.75 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2026-05-31 | Fidelity Total Market Index Fund | FSKAX | 12,140 | 71,019 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2026-05-31 | Fidelity Series Total Market Index Fund | FCFMX | 9,232 | 54,007.2 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2026-05-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 10,958 | 64,104.3 | 0.0002 |
| FIDELITY CONCORD STREET TRUST | 2026-05-31 | Fidelity Extended Market Index Fund | FSMAX | 32,203 | 188,387.55 | 0.0004 |
| Dimensional ETF Trust | 2026-04-30 | Dimensional US Sustainability Core 1 ETF | DFSU | 201 | 1,199.97 | 0.0001 |